BASF introduces Kollicoat MAE 100-55 — a new opportunity for the formulation of pharmaceutical enteric film coatings
Enabling direct substitution in commercial enteric pharmaceutical formulations.
BASF is introducing Kollicoat MAE 100-55 at the 10th World Meeting on Pharmaceutics, Biopharmaceuticals and Pharmaceutical Technology (PBP) in Glasgow, UK, 4–7 April 2016.
Kollicoat MAE 100-55 is the latest addition in BASF’s comprehensive portfolio of functional excipients for Instant & Modified Release. As a new reliable source for this type of coating polymer, Kollicoat MAE 100-55 can directly replace comparable pH >5.5 enteric release materials in commercial formulations. As it matches the release profile and complies with applicable regulatory monographs, Kollicoat MAE 100-55 can be used today without re-registration.
Moreover, the superior size of the dried powder particles delivers dust free handling, thus making operations easy, efficient and clean. Beyond its advantages in handling, Kollicoat MAE 100-55 provides equivalent drug release as existing comparable products in the market.
“Kollicoat MAE 100-55 extends our offer of pH >5.5 enteric release coatings based on methacrylic acid-ethylacrylate copolymer, providing pharmaceutical manufacturers more flexibility and supply security,” says Kai Sievert, Head of Global Marketing Pharma Solutions at BASF.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.